Long-Term Survival and Tumor Recurrence in Patients with Superficial Esophageal Cancer after Complete Non-Curative Endoscopic Resection: A Single-Center Case Series

Lee, Jiwan; Cho, Charles J.; Kim, Do Hoon; Ahn, Ji Yong; Lee, Jeong Hoon; Choi, Kee Don; Song, Ho June; Park, Sook Ryun; Lee, Hyun Joo; Kim, Yong Hee; Lee, Gin Hyug; Jung, Hwoon‐Yong; Kim, Sung‐Bae; Kim, Jong Hoon; Park, Seung-Il

doi:10.5946/ce.2018.025

Cited by 3 publications

(6 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[140][141][142] General medical practice includes radiation and chemotherapy, which lead to various other complications leading the patients in much stress. [143][144][145] Recently, nanomedicine has played a vital role in the treatment of cancer overcoming several side effects of traditional medicines, although nanodelivery systems loaded with drugs or plant-based bioactive compounds face critical challenges in the delivery of the bioactive compounds to the target sites and through the delivery systems. [146][147][148][149] Microfluidization techniques try to solve some disadvantages during the production of those nanodelivery systems developed using anticancer drugs or plant-based bioactive compounds.…”

Section: Anticancer Effectmentioning

confidence: 99%

Microfluidization trends in the development of nanodelivery systems and applications in chronic disease treatments

Ganesan

Karthivashan

Park

et al. 2018

IJN

View full text Add to dashboard Cite

Plant bioactive compounds are known for their extensive health benefits and therefore have been used for generations in traditional and modern medicine to improve the health of humans. Processing and storage instabilities of the plant bioactive compounds, however, limit their bioavailability and bioaccessibility and thus lead researchers in search of novel encapsulation systems with enhanced stability, bioavailability, and bioaccessibility of encapsulated plant bioactive compounds. Recently many varieties of encapsulation methods have been used; among them, microfluidization has emerged as a novel method used for the development of delivery systems including solid lipid nanocarriers, nanoemulsions, liposomes, and so on with enhanced stability and bioavailability of encapsulated plant bioactive compounds. Therefore, the nanodelivery systems developed using microfluidization techniques have received much attention from the medical industry for their ability to facilitate controlled delivery with enhanced health benefits in the treatment of various chronic diseases. Many researchers have focused on plant bioactive compound-based delivery systems using microfluidization to enhance the bioavailability and bioaccessibility of encapsulated bioactive compounds in the treatment of various chronic diseases. This review focuses on various nanodelivery systems developed using microfluidization techniques and applications in various chronic disease treatments.

show abstract

Section: Anticancer Effectmentioning

confidence: 99%

Microfluidization trends in the development of nanodelivery systems and applications in chronic disease treatments

Ganesan

Karthivashan

Park

et al. 2018

IJN

View full text Add to dashboard Cite

show abstract

“…However, they included patients who underwent non-complete resection and had a positive resection margin. In a recent issue of Clinical Endoscopy , Lee et al analyzed long-term survival and tumor recurrence in patients with superficial esophageal cancer after complete non-curative endoscopic resection [ 12 ]. In their study, non-curative resection was defined as the presence of submucosal and/or lymphovascular invasion on endoscopic resection pathology.…”

mentioning

confidence: 99%

“…Patients who were margin positive were excluded from the non-complete resection group. The 5-year overall survival rate was 72.9% in the close observation group ( n =10) and 82.1% in the additional treatment group ( n =14; p =0.958) [ 12 ]. In addition, they reported similar 5-year cumulative incidences of primary esophageal cancer recurrence (10.0% vs. 16.4%, p =0.558) and metachronous esophageal cancer recurrence (16.7% vs. 26.7%, p =0.667) between the two groups [ 12 ].…”

mentioning

confidence: 99%

“…The 5-year overall survival rate was 72.9% in the close observation group ( n =10) and 82.1% in the additional treatment group ( n =14; p =0.958) [ 12 ]. In addition, they reported similar 5-year cumulative incidences of primary esophageal cancer recurrence (10.0% vs. 16.4%, p =0.558) and metachronous esophageal cancer recurrence (16.7% vs. 26.7%, p =0.667) between the two groups [ 12 ]. Given these results, the authors concluded that if the esophageal lesion was resected completely, even though it was non-curatively resected, close observation might be an option for patients who are medically unfit to receive additional therapy.…”

mentioning

confidence: 99%

“…It is meaningful that Lee et al reported the long-term outcomes of treatment and observation groups after non-curative resection of esophageal cancer among Korean patients [ 12 ]. It is particularly meaningful that their study showed close observation to be a potential option for patients who have undergone a complete non-curative resection and are unable to receive additional therapy considering the high mortality associated with esophagectomy.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Non-Curative Endoscopic Resection for Superficial Esophageal Cancer

Kim

Park

2018

Clin Endosc

View full text Add to dashboard Cite

Close Observation versus Additional Surgery after Noncurative Endoscopic Resection of Esophageal Squamous Cell Carcinoma

et al. 2021

Self Cite

View full text Add to dashboard Cite

Introduction: After noncurative endoscopic submucosal dissection (ESD) of superficial esophageal squamous cell carcinoma (SESCC), additional esophagectomy is generally recommended. However, considering its high mortality and morbidity, it is uncertain if additional surgery improves the clinical outcomes. This study aimed to compare the clinical outcomes between patients who were observed without additional treatment and those who underwent radical esophagectomy. Methods: A total of 52 patients with SESCC who underwent complete but noncurative ESD from January 2008 to December 2016 at the Samsung Medical Center and Asan Medical Center in Korea were retrospectively analyzed. Clinicopathologic characteristics and oncologic outcomes were compared between the observation group (n = 23) and the additional surgery group (n = 29). Results: During a mean follow-up of 34.4 and 41.7 months, respectively, the rates of death (observation vs. surgery, 17.4 vs. 10.3%; p = 0.686), recurrence (observation vs. surgery, 13 vs. 17.2%; p = 1.000), and disease-specific death (observation vs. surgery, 4.3 vs. 6.9%; p = 1.000) did not significantly differ between the 2 groups. The 3-year overall survival was 86.3 and 96.4%, respectively (p = 0.776). The 3-year recurrence-free survival (observation vs. surgery, 85.0 vs. 88.7%; p = 0.960) and disease-specific survival (observation vs. surgery, 95.2 vs. 96.4%; p = 0.564) also did not significantly differ. Conclusions: The clinical outcomes of close observation of noncuratively resected SESCC are comparable to those of additional surgery, at least in the midterm. The wait-and-see strategy could be a feasible management option after noncurative ESD of SESCC in selected patients.

show abstract

Long-Term Survival and Tumor Recurrence in Patients with Superficial Esophageal Cancer after Complete Non-Curative Endoscopic Resection: A Single-Center Case Series

Cited by 3 publications

References 26 publications

Microfluidization trends in the development of nanodelivery systems and applications in chronic disease treatments

Microfluidization trends in the development of nanodelivery systems and applications in chronic disease treatments

Non-Curative Endoscopic Resection for Superficial Esophageal Cancer

Close Observation versus Additional Surgery after Noncurative Endoscopic Resection of Esophageal Squamous Cell Carcinoma

Contact Info

Product

Resources

About